Company intelligence / Profile preview

ImmunSkills SA

Monthey, Valais, Switzerlands-ge.com ↗

Ownership: Private
Development stage: Other

Overview

ImmunSkills has developed an advanced cell therapy platform that genetically modifies allogeneic NK cells to resist the hostile tumor microenvironment. Their technology has shown promising in-vitro results and is preparing for animal model studies targeting solid tumors such as pancreatic cancer. The company offers scalable R&D and GMP production capabilities for clients developing new CAR-based cell therapies.

Therapeutic areas: Oncology
Modalities: Allogeneic cell therapiesGenetically modified Natural Killer (NK) cellsChimeric Antigen Receptor (CAR)-engineered immune cells
Industry: Biotech

Partnerships

University of Applied Sciences (for development/testing of anti-pancreatic cancer CAR construct)The Ark Foundation/BioArk Monthey technology site support

Beyond the preview

Go deeper on ImmunSkills SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunSkills SA.

Explore the full profile